Hoth Therapeutics Inc (HOTH)

Apr 21, 2025

Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX

Apr 21, 2025

Apr 18, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Apr 18, 2025

Apr 18, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada

Apr 18, 2025

Apr 17, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa

Apr 17, 2025

Apr 17, 2025

Revolutionary RNA Cancer Treatment Gets Japanese Patent: Hoth's KIT Gene Therapy Targets Multiple Cancers - Stock Titan

Apr 17, 2025

Apr 16, 2025

Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus

Apr 16, 2025

Apr 15, 2025

Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - TradingView

Apr 15, 2025

Apr 15, 2025

Hoth Therapeutics reports progress in pruritus treatment trial - Investing.com

Apr 15, 2025

Apr 15, 2025

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial - Longview News-Journal

Apr 15, 2025

Apr 03, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com Nigeria

Apr 03, 2025

Apr 02, 2025

Hoth Therapeutics (HOTH) Reports Promising Data for Alzheimer's Candidate HT-ALZ - GuruFocus

Apr 02, 2025

Apr 02, 2025

Hoth Flat on Hookup with Washington Univ. - Baystreet.ca

Apr 02, 2025

Apr 02, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India

Apr 02, 2025

Apr 02, 2025

Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener

Apr 02, 2025

Apr 02, 2025

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ - Longview News-Journal

Apr 02, 2025

Apr 02, 2025

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PR Newswire

Apr 02, 2025

Apr 01, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 01, 2025

Mar 31, 2025

Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks

Mar 31, 2025

Mar 31, 2025

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage - PR Newswire

Mar 31, 2025

Mar 28, 2025

Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025

Mar 28, 2025

Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz

Mar 28, 2025

Mar 28, 2025

Hoth Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025

Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com

Mar 26, 2025

Mar 26, 2025

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com

Mar 26, 2025

Mar 26, 2025

Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan

Mar 26, 2025

Mar 24, 2025

Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 24, 2025

Mar 20, 2025

Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World

Mar 20, 2025

Mar 19, 2025

Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Mar 19, 2025

Mar 19, 2025

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Hoth reports progress in GIST treatment with HT-KIT - Investing.com India

Mar 18, 2025

Mar 18, 2025

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire

Mar 18, 2025

Mar 18, 2025

Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan

Mar 18, 2025

Mar 17, 2025

Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World

Mar 17, 2025

Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia

Mar 10, 2025

Mar 10, 2025

Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

Hoth Dips on Drug Application - Baystreet.ca

Mar 10, 2025

Mar 10, 2025

Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks

Mar 10, 2025

Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India

Mar 10, 2025

Mar 10, 2025

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire

Mar 10, 2025

Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India

Mar 05, 2025

Mar 05, 2025

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks

Mar 05, 2025